Corbus Pharmaceuticals Holdings (LTS:0SZI) Ending Cash Position : $14.77 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Ending Cash Position?

Corbus Pharmaceuticals Holdings's Ending Cash Position for the quarter that ended in Mar. 2024 was $14.77 Mil.

Corbus Pharmaceuticals Holdings's quarterly Ending Cash Position increased from Sep. 2023 ($11.92 Mil) to Dec. 2023 ($14.39 Mil) and increased from Dec. 2023 ($14.39 Mil) to Mar. 2024 ($14.77 Mil).

Corbus Pharmaceuticals Holdings's annual Ending Cash Position declined from Dec. 2021 ($25.68 Mil) to Dec. 2022 ($17.67 Mil) and declined from Dec. 2022 ($17.67 Mil) to Dec. 2023 ($14.39 Mil).

Corbus Pharmaceuticals Holdings Ending Cash Position Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Ending Cash Position Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

31.75

86.45

25.68

17.67

14.39

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															7.99	9.02	11.92	14.39	14.77

Corbus Pharmaceuticals Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Corbus Pharmaceuticals Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	17.673	+	-3.279
	=	14.39

Corbus Pharmaceuticals Holdings's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	14.393	+	0.37999999999999
	=	14.77

Corbus Pharmaceuticals Holdings Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CRBP:USA

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Headlines

No Headlines